A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: Time course and mechanisms

The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

Dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice

Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice

Metabolomics in the context of systems biology: Bridging Traditional Chinese Medicine and molecular pharmacology

Amlodipine and atorvastatin in atherosclerosis: A review of the potential of combination therapy

On the assessment of adverse drug reactions from spontaneous reporting systems: The influence of under-reporting on odds ratios

Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication

Alpha- and beta-adrenergic influences on the tissue and urokinase plasminogen activator systems

Toxicological evaluation and risk assessment of chemical mixtures

Increase of fungitoxicity of mercuric chloride by methionine, ethionine and s methylcysteine